CStone's GAVRETO included in China's national reimbursement drug list

CStone Pharmaceuticals announced the inclusion of its drug, GAVRETO (pralsetinib, 100 mg), in China's latest National Reimbursement Drug List (NRDL). This inclusion is set to become effective on January 1, 2026, marking a significant milestone for the company.

GAVRETO is an oral targeted therapy approved in China for treating adults with locally advanced or metastatic RET fusion-positive Non-Small Cell Lung Cancer (NSCLC), as well as adult and pediatric patients (12 years and older) with advanced or metastatic RET-mutant Medullary Thyroid Carcinoma (MTC) and RET fusion-positive thyroid cancer requiring systemic therapy. The drug is also approved in Hong Kong and Taiwan, China, for similar indications.

CStone discovered GAVRETO with Blueprint Medicines (acquired by Sanofi in July 2025) and holds exclusive development and commercialization rights in Greater China. In November 2023, CStone also entered an exclusive agreement with Shanghai Allist Pharmaceuticals Co., Ltd. for the commercialization of GAVRETO in Mainland China.